Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study

Abstract

Background Human papillomavirus (HPV)‐related oropharyngeal cancer screening is being explored in research studies, but strategies to identify an appropriate population are not established. The authors evaluated whether a screening population could be enriched for participants with oncogenic HPV biomarkers using risk factors for oral HPV. Methods Participants were enrolled at Johns Hopkins Hospitals and Mount Sinai Icahn School of Medicine. Eligible participants were either men aged 30 years or older who had two or more lifetime oral sex partners and a personal history of anogenital dysplasia/cancer or partners of patients who had HPV‐related cancer. Oral rinse and serum samples were tested for oncogenic HPV DNA, RNA, and E6 or E7 antibodies, respectively. Participants with any biomarker were considered at‐risk. Results Of 1108 individuals, 7.3% had any oncogenic oral HPV DNA, and 22.9% had serum antibodies for oncogenic HPV E6 or E7. Seventeen participants (1.5%) had both oral and blood biomarkers. HPV type 16 (HPV16) biomarkers were rarer, detected in 3.7% of participants, including 20 with oral HPV16 DNA and 22 with HPV16 E6 serum antibodies (n = 1 had both). In adjusted analysis, living with HIV (adjusted odds ratio, 2.65; 95% CI, 1.60–4.40) and older age (66–86 vs. 24–45 years; adjusted odds ratio, 1.70; 95% CI, 1.07–2.70) were significant predictors of being at risk. Compared with the general population, the prevalence of oral HPV16 (1.8% vs. 0.9%), any oncogenic oral HPV DNA (7.3% vs. 3.5%), and HPV16 E6 antibodies (2.2% vs. 0.3%) was significantly elevated. Conclusions Enrichment by the eligibility criteria successfully identified a population with higher biomarker prevalence, including HPV16 biomarkers, that may be considered for screening trials. Most in this group are still expected to have a low risk of oropharyngeal cancer.

Delaying age at first sexual intercourse provides protection against oral cavity cancer: a mendelian randomization study

“…The specific transmission routes of HPV are also of great significance to the prevention and control of OCC. Although it can be transmitted through contact, sexual transmission, obviously including oral sex, is the main route of HPV infection ( 29 – 31 ). In terms of oral cavity, HPV colonizes the oral cavity in various ways.…”

Human papillomavirus circulating tumor DNA assays as a mechanism for head and neck cancer equity in rural regions of the United States

“…Though there are no current recommendations for population screening for HPV-OPC, further refinement of high-risk groups ( 65 ) that may benefit from screening could potentially allow for the use of ctDNA for screening in the future. For example, a recent study applied ctDNA testing to patients with clinical findings concerning for OPC, and correctly identified HPV-OPC in a subset of patients with positive testing ( 66 ).…”

Oral HPV-associated dysplasia: is koilocytic dysplasia a separate entity?

“…The pursuit of HPV testing is expressly advised in instances where histological evidence strongly indicates HPV-OED. Screening for HPV infection in isolation is discouraged due to an imperfect balance of advantages and potential drawbacks (37). This imbalance is primarily attributed to the transient nature of most oral HPV DNA, increasing the probability of false positives.…”